Last 46 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 148.05 | 58.48 | 81.30 | 605.91 | 715.91 | 2.89 | 2.89 | 83.78 | 113.55 | 57.84 | 56.76 | — | — | 6.12 | 6.64 | — | — | — | — | — | — |
| — | +1920.5% | +2711.1% | +623.2% | +530.5% | -95.0% | -94.9% | — | — | +844.7% | +754.4% | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.82 | 3.37 | 4.69 | 4.30 | 5.08 | 4.73 | 4.73 | 3.88 | 5.25 | 4.89 | 4.80 | 5.06 | 9.00 | 1.95 | 2.12 | 5.57 | 3.34 | 5.31 | 7.95 | 15.11 | 15.77 |
| — | -28.6% | -0.7% | +10.9% | -3.4% | -3.2% | -1.4% | -23.4% | -41.6% | +150.3% | +126.4% | -9.1% | +169.6% | -63.3% | -73.4% | -63.2% | -78.8% | -72.1% | -36.5% | -20.9% | -16.7% | |
| P/B Ratio | 2.12 | 1.47 | 2.05 | 1.86 | 2.20 | 2.11 | 2.11 | 3.26 | 4.42 | 3.97 | 3.90 | 4.15 | 3.88 | 2.60 | 2.82 | 3.92 | 2.35 | 2.52 | 3.77 | 5.78 | 6.03 |
| — | -30.3% | -3.1% | -42.9% | -50.2% | -46.8% | -45.8% | -21.5% | +13.7% | +52.7% | +38.1% | +5.9% | +65.2% | +3.2% | -25.2% | -32.1% | -61.0% | -55.8% | -57.1% | -35.3% | -31.8% | |
| P/FCF | 265.85 | 142.46 | 198.06 | 346.84 | 409.81 | — | — | 38.71 | 52.46 | — | — | — | — | 5.15 | 5.59 | — | — | — | — | — | — |
| — | — | — | +796.0% | +681.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 117.51 | 163.68 | — | — | 502.39 | 502.05 | — | — | — | — | — | — | 8.22 | 8.98 | — | — | — | — | — | — |
| — | -76.6% | -67.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 1073.86 | 1495.73 | — | — | — | — | — | — | — | — | — | — | 8.50 | 9.29 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.7% | 17.0% | 17.0% | -17.1% | -17.1% | 39.7% | 39.7% | -17.4% | -17.4% | 41.1% | 41.1% | 93.9% | -107.8% | 60.9% | 60.9% | -68.9% | -68.9% | 325.1% | -57.9% | 8.2% | 56.0% |
| — | -57.1% | -57.1% | +1.7% | +1.7% | -3.5% | -3.5% | -118.5% | +83.9% | -32.6% | -32.6% | +236.2% | -56.5% | -81.3% | +205.2% | -939.5% | -223.1% | +1308.3% | -384.3% | +111.8% | +180.3% | |
| Operating Margin | -10.0% | 0.3% | 0.3% | -13.2% | -13.2% | -1.3% | -1.3% | -5.0% | -5.0% | -9.0% | -9.0% | -30.6% | -58.1% | 21.0% | 21.0% | -94.0% | -94.0% | -99.4% | -97.4% | -92.9% | -92.9% |
| — | +124.7% | +124.7% | -163.9% | -163.9% | +85.9% | +85.9% | +83.7% | +91.4% | -143.0% | -143.0% | +67.5% | +38.2% | +121.1% | +121.5% | -1.2% | -1.2% | +6.4% | -25.7% | -244.0% | -244.0% | |
| Net Margin | 83.3% | 5.7% | 5.7% | 0.7% | 0.7% | 163.8% | 163.8% | 3.7% | 3.7% | 8.4% | 8.4% | -22.2% | -42.2% | 31.6% | 31.6% | -88.2% | -88.2% | -161.2% | -80.6% | -26.8% | -46.4% |
| — | -96.5% | -96.5% | -80.4% | -80.4% | +1841.2% | +1841.2% | +116.5% | +108.7% | -73.3% | -73.3% | +74.8% | +52.1% | +119.6% | +139.2% | -229.4% | -90.1% | -99.5% | -59.8% | +57.3% | +26.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 45.3% | 0.6% | 0.6% | 0.1% | 0.1% | 18.3% | 22.6% | 0.8% | 0.8% | 1.7% | 1.7% | -4.6% | -4.4% | 10.5% | 11.7% | -15.5% | -13.3% | -19.1% | -8.6% | -2.6% | -4.5% |
| — | -96.6% | -97.2% | -89.9% | -90.0% | +967.7% | +1209.4% | +117.0% | +117.8% | -83.7% | -85.3% | +70.7% | +67.0% | +155.1% | +236.2% | -506.8% | -196.0% | -130.7% | -2.9% | +65.0% | +47.6% | |
| ROA | 30.3% | 0.5% | 0.5% | 0.1% | 0.1% | 12.8% | 14.9% | 0.5% | 0.5% | 1.0% | 1.0% | -2.6% | -2.6% | 6.5% | 7.2% | -9.6% | -8.9% | -13.6% | -6.3% | -1.9% | -3.5% |
| — | -96.4% | -96.9% | -88.1% | -88.2% | +1152.0% | +1368.8% | +117.7% | +117.9% | -84.2% | -86.0% | +72.5% | +70.5% | +147.6% | +214.2% | -395.7% | -155.3% | -118.8% | -9.3% | +63.1% | +42.7% | |
| ROIC | -4.1% | 0.0% | 0.0% | -1.0% | -1.1% | -0.1% | -0.1% | -0.9% | -0.9% | -1.6% | -1.7% | -6.4% | -6.0% | 6.8% | 8.7% | -22.6% | -21.5% | -19.6% | -13.6% | -9.9% | -11.9% |
| — | +124.1% | +118.9% | -22.0% | -18.0% | +93.4% | +92.2% | +86.6% | +85.0% | -123.9% | -120.2% | +71.6% | +72.0% | +134.6% | +163.7% | -128.5% | -80.9% | -0.3% | +31.5% | -208.1% | -235.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.05 | 0.05 | 0.04 | 0.04 | 0.00 | 0.00 | 0.04 | 0.04 |
| — | -8.6% | -8.6% | -32.8% | -32.8% | -31.2% | -31.2% | +0.4% | +0.4% | +134.8% | +134.8% | +173.2% | +173.2% | +10120.6% | +10120.6% | +13.1% | +13.1% | -98.6% | -99.4% | -50.0% | -46.4% | |
| Debt / EBITDA | — | 23.80 | 23.80 | — | — | 77.37 | 77.37 | — | — | — | — | — | — | 0.70 | 0.70 | — | — | — | — | — | — |
| — | -69.2% | -69.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.96 | 5.64 | 5.64 | 4.96 | 4.96 | 4.65 | 4.65 | 2.83 | 2.83 | 2.81 | 2.81 | 2.72 | 2.72 | 3.20 | 3.20 | 2.37 | 2.37 | 3.18 | 3.18 | 3.89 | 3.89 |
| — | +21.4% | +21.4% | +75.2% | +75.2% | +65.6% | +65.6% | +4.1% | +4.1% | -12.2% | -12.2% | +14.7% | +14.7% | +0.7% | +0.7% | -39.0% | -39.0% | -27.9% | +20.7% | +16.1% | +16.1% | |
| Quick Ratio | 4.83 | 5.50 | 5.50 | 4.83 | 4.83 | 4.51 | 4.51 | 2.70 | 2.70 | 2.68 | 2.68 | 2.60 | 2.60 | 3.04 | 3.04 | 2.21 | 2.21 | 3.03 | 3.03 | 3.77 | 3.77 |
| — | +21.9% | +21.9% | +79.1% | +79.1% | +68.0% | +68.0% | +3.9% | +3.9% | -11.8% | -11.8% | +17.3% | +17.3% | +0.3% | +0.3% | -41.4% | -41.4% | -29.5% | +20.0% | +17.0% | +17.0% | |
| Interest Coverage | -19.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -203.29 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HCM stock.
HUTCHMED (China) Limited's current P/E is 148.0x. The average P/E over the last 4 quarters is 365.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
HUTCHMED (China) Limited's current operating margin is -10.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking HUTCHMED (China) Limited's business trajectory between earnings reports.